Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services, has announced an agreement to acquire the DNA and RNA business of Officinae Bio. This acquisition is expected to enhance Maravai and its subsidiary, TriLink BioTechnologies, in their ability to support customers in the development of cutting-edge nucleic acid-based therapies.
The acquisition will enhance Maravai and its subsidiary, TriLink BioTechnologies, by expanding their capabilities in supporting the development of innovative nucleic acid-based therapies. Officinae Bio’s advanced technology platform allows for the testing of various combinations of CAP analogs, chemistry modifications, and sequence designs, which is crucial for the discovery and development of mRNA-based therapeutics. This portfolio of services is a strong complement to Maravai’s existing nucleic acid production offerings, providing significant benefits to customers focused on cutting-edge therapeutic development.
“We are thrilled to integrate Officinae Bio’s unique sequence design technology into our Nucleic Acid Production business,” said Trey Martin, CEO of Maravai LifeSciences. “Their AI-driven approach and innovative team bring a distinct advantage to our mRNA capabilities, helping us accelerate manufacturing innovation and support the growth of our customers’ breakthrough therapies.”
Justin Barbosa, General Manager and Vice President of TriLink Discovery, added, “Officinae Bio’s integration of leading science and AI methodologies creates a unique experience for customers in sequence design. This acquisition solidifies TriLink’s position as a leader in mRNA design, customization, and manufacturing, all while delivering a personalized, high-touch customer experience.”
Davide De Lucrezia, CEO and co-founder of Officinae Bio, commented, “Joining forces with Maravai and TriLink is an exciting opportunity for our team. Their trusted leadership and quality align perfectly with our vision for collaboration and continuous improvement in the life sciences. We’re committed to supporting our customers and believe this acquisition will enhance our ability to meet their needs. Additionally, we look forward to strengthening our contributions to GMP manufacturing of key enzymes for nucleic acid-based vaccine and therapeutic applications.”
The transaction is subject to customary closing conditions and regulatory approvals, and is expected to close in early 2025.
About Maravai LifeSciences
Maravai LifeSciences is a leading life sciences company that provides essential products and services to support the development of drug therapies, diagnostics, novel vaccines, and research on human diseases. Its subsidiaries lead the industry in nucleic acid synthesis, biologics safety testing, and other essential services to biopharmaceutical, vaccine, diagnostics, and gene therapy companies.
About Officinae Bio
Officinae Bio is a technology company focused on developing innovative platforms to support the design of biologically engineered therapeutics. The company leverages AI-enabled methodologies to advance nucleic acid manufacturing, driving research in areas such as gene-modified cell therapy, gene therapy, and RNA therapeutics.
